Ebenbuild today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.

Twinhale is the first scalable simulation tool that enables physiologically accurate, patient-specific predictions of drug deposition in the lungs. Built on Ebenbuild’s proprietary technology platform, it offers pharmaceutical and medtech companies a cost-efficient technology to digitally simulate pulmonary drug delivery – potentially reducing trial failure rates and costs as well as time-to-market.

Ebenbuild has already applied its Twinhale software in pilot studies with PARI Pharma and Pieris Pharmaceuticals. In a validation study, Twinhale predicted local drug deposition with unprecedented accuracy, outperforming existing models and enabling design decisions that are typically inaccessible through in vivo or in vitro testing.

Backed by HTGF, Bayern Kapital and angel investors, Ebenbuild operates in a rapidly growing Euro >5 billion in silico trials market and is positioning itself to enter the clinical decision support systems (CDSS) and personalized medicine markets, collectively estimated at over €300 billion by 2030. The EIC grant provides non-dilutive capital and validation from one of the most competitive tech funding programs in Europe.

“Our vision is to become the leading health intelligence platform for respiratory diseases,” said Dr. Kei Müller, CEO and Co-founder of the Company. “Twinhale is just the beginning. The very same core platform will power future regulated products for mechanical ventilation optimization and chronic respiratory disease management.”

Dr. Maximilian Grill, Head of In Silico Trials at Ebenbuild, added: “With Twinhale, we are not only reducing attrition rates in respiratory drug development – we are also generating first-of-its-kind datasets that can drive regulatory acceptance and unlock companion diagnostic strategies in the future.”

The Company’s long-term roadmap spans from preclinical simulations to clinical-grade decision support systems. As a follow-up product, Ebenbuild develops a software for optimizing mechanical ventilation in patients with lung complications – a Euro 10 billion market segment with strong clinical demand rapid feedback cycles, and clear economic benefits.